Brand Name | Status | Last Update |
---|---|---|
adcirca | New Drug Application | 2024-11-13 |
alyq | ANDA | 2024-01-10 |
cialis | New Drug Application | 2024-11-13 |
entadfi | New Drug Application | 2023-01-12 |
finasteride and tadalafil | ANDA | 2025-03-24 |
n/a | ANDA | 2024-12-20 |
opsynvi | New Drug Application | 2024-04-02 |
tadalafil | ANDA | 2025-03-21 |
tadliq | New Drug Application | 2022-10-17 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | 1 | — | 1 |
Drug common name | Tadalafil |
INN | tadalafil |
Description | Tadalafil is a pyrazinopyridoindole that is 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione substituted at position 2 by a methyl group and at position 6 by a 1,3-benzodioxol-5-yl group (the 6R,12aR-diastereomer). A phosphodiesterase V inhibitor inhibitor, currently marketed in pill form for treating erectile dysfunction under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension. It has a role as an EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor and a vasodilator agent. It is a pyrazinopyridoindole and a member of benzodioxoles. |
Classification | Small molecule |
Drug class | phosphodiesterase type 5 inhibitors (PDE5) inhibitors: (PDE5) inhibitors containing a sulfonamide moiety |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O |
PDB | — |
CAS-ID | 171596-29-5 |
RxCUI | — |
ChEMBL ID | CHEMBL779 |
ChEBI ID | 71940 |
PubChem CID | 110635 |
DrugBank | DB00820 |
UNII ID | 742SXX0ICT (ChemIDplus, GSRS) |